Prevalence study of intermittent hormonal therapy of Prostate Cancer patients in Spain [version 2; peer review: 2 approved]
Background: Although intermittent androgen deprivation therapy was introduced many years ago to improve patients’ quality of life with the same carcinologic efficiency as continuous hormonal therapy, recent data suggest that intermittency could be underutilised. This study aims to estimate the preva...
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
F1000 Research Ltd
2022-04-01
|
| Series: | F1000Research |
| Subjects: | |
| Online Access: | https://f1000research.com/articles/10-1069/v2 |
| _version_ | 1797989743850422272 |
|---|---|
| author | Iratxe Urreta Jose Ignacio Pijoan José Antonio Cordero Ariadna Auladell-Rispau Ignasi Gich Javier Zamora Luis Carlos Saiz Xavier Bonfill-Cosp |
| author_facet | Iratxe Urreta Jose Ignacio Pijoan José Antonio Cordero Ariadna Auladell-Rispau Ignasi Gich Javier Zamora Luis Carlos Saiz Xavier Bonfill-Cosp |
| author_sort | Iratxe Urreta |
| collection | DOAJ |
| description | Background: Although intermittent androgen deprivation therapy was introduced many years ago to improve patients’ quality of life with the same carcinologic efficiency as continuous hormonal therapy, recent data suggest that intermittency could be underutilised. This study aims to estimate the prevalence of prostate cancer patients receiving intermittent androgen deprivation therapy in Spain. Methods: A retrospective, longitudinal study was conducted using electronic drug dispensation data from four Spanish autonomous communities, which encompass 17.23 million inhabitants (36.22% of the total population in Spain). We estimated intermittent androgen therapy use (%IAD) and the prevalence of patients under intermittent androgen therapy in reference to the total number of PC patients using hormonal therapy (P IAD) and stratified by region. Other outcome variables included the pharmaceutical forms dispensed and the total direct annual expenditure on androgen deprivation therapy‐associated medications. Results: A total of 863,005 dispensations corresponding to a total of 65,752 men were identified, treated with either luteinizing hormone-releasing hormone (LHRH) analogues (353,162) administered alone or in combination with anti‐androgens (509,843). Overall, the mean (±SD) age of the patients was 76.9 (±10.4) years. Results revealed that the mean annual P IAD along the study was 6.6% in the total population studied, and the overall %IAD during the five‐year study period was 5.6%. The mean cost of hormonal therapy per year was 25 million euros for LHRH analogues and 6.3 million euros for anti-androgens. Conclusions: Few prostate cancer patients in Spain use the intermittent androgen deprivation therapy suggesting underutilization of a perfectly valid option for a significant proportion of patients, missing the opportunity to improve their quality of life and to reduce costs for the National Health Service with comparable overall survival rates than continuous therapy. |
| first_indexed | 2024-04-11T08:25:19Z |
| format | Article |
| id | doaj.art-16a6dadf5ed349fbbc0a1876ffbb488d |
| institution | Directory Open Access Journal |
| issn | 2046-1402 |
| language | English |
| last_indexed | 2024-04-11T08:25:19Z |
| publishDate | 2022-04-01 |
| publisher | F1000 Research Ltd |
| record_format | Article |
| series | F1000Research |
| spelling | doaj.art-16a6dadf5ed349fbbc0a1876ffbb488d2022-12-22T04:34:47ZengF1000 Research LtdF1000Research2046-14022022-04-0110131327Prevalence study of intermittent hormonal therapy of Prostate Cancer patients in Spain [version 2; peer review: 2 approved]Iratxe Urreta0https://orcid.org/0000-0003-0498-6033Jose Ignacio Pijoan1José Antonio Cordero2https://orcid.org/0000-0002-3167-2315Ariadna Auladell-Rispau3https://orcid.org/0000-0002-0364-4827Ignasi Gich4Javier Zamora5Luis Carlos Saiz6Xavier Bonfill-Cosp7CIBER of Epidemiology and Public Health (CIBERESP), Madrid, SpainCIBER of Epidemiology and Public Health (CIBERESP), Madrid, SpainSchool of Health Sciences Blanquerna, University Ramon Llull, Barcelona, SpainIberoamerican Cochrane Centre, Biomedical Research Institute Sant Pau (IIB Sant Pau), Barcelona, SpainIberoamerican Cochrane Centre, Biomedical Research Institute Sant Pau (IIB Sant Pau), Barcelona, SpainCIBER of Epidemiology and Public Health (CIBERESP), Madrid, SpainUnit of Innovation and Organization, Navarre Health Service, Pamplona, SpainIberoamerican Cochrane Centre, Biomedical Research Institute Sant Pau (IIB Sant Pau), Barcelona, SpainBackground: Although intermittent androgen deprivation therapy was introduced many years ago to improve patients’ quality of life with the same carcinologic efficiency as continuous hormonal therapy, recent data suggest that intermittency could be underutilised. This study aims to estimate the prevalence of prostate cancer patients receiving intermittent androgen deprivation therapy in Spain. Methods: A retrospective, longitudinal study was conducted using electronic drug dispensation data from four Spanish autonomous communities, which encompass 17.23 million inhabitants (36.22% of the total population in Spain). We estimated intermittent androgen therapy use (%IAD) and the prevalence of patients under intermittent androgen therapy in reference to the total number of PC patients using hormonal therapy (P IAD) and stratified by region. Other outcome variables included the pharmaceutical forms dispensed and the total direct annual expenditure on androgen deprivation therapy‐associated medications. Results: A total of 863,005 dispensations corresponding to a total of 65,752 men were identified, treated with either luteinizing hormone-releasing hormone (LHRH) analogues (353,162) administered alone or in combination with anti‐androgens (509,843). Overall, the mean (±SD) age of the patients was 76.9 (±10.4) years. Results revealed that the mean annual P IAD along the study was 6.6% in the total population studied, and the overall %IAD during the five‐year study period was 5.6%. The mean cost of hormonal therapy per year was 25 million euros for LHRH analogues and 6.3 million euros for anti-androgens. Conclusions: Few prostate cancer patients in Spain use the intermittent androgen deprivation therapy suggesting underutilization of a perfectly valid option for a significant proportion of patients, missing the opportunity to improve their quality of life and to reduce costs for the National Health Service with comparable overall survival rates than continuous therapy.https://f1000research.com/articles/10-1069/v2intermittent androgen deprivation therapy (IAD) LHRH analogues prostate cancer appropriatenesseng |
| spellingShingle | Iratxe Urreta Jose Ignacio Pijoan José Antonio Cordero Ariadna Auladell-Rispau Ignasi Gich Javier Zamora Luis Carlos Saiz Xavier Bonfill-Cosp Prevalence study of intermittent hormonal therapy of Prostate Cancer patients in Spain [version 2; peer review: 2 approved] F1000Research intermittent androgen deprivation therapy (IAD) LHRH analogues prostate cancer appropriateness eng |
| title | Prevalence study of intermittent hormonal therapy of Prostate Cancer patients in Spain [version 2; peer review: 2 approved] |
| title_full | Prevalence study of intermittent hormonal therapy of Prostate Cancer patients in Spain [version 2; peer review: 2 approved] |
| title_fullStr | Prevalence study of intermittent hormonal therapy of Prostate Cancer patients in Spain [version 2; peer review: 2 approved] |
| title_full_unstemmed | Prevalence study of intermittent hormonal therapy of Prostate Cancer patients in Spain [version 2; peer review: 2 approved] |
| title_short | Prevalence study of intermittent hormonal therapy of Prostate Cancer patients in Spain [version 2; peer review: 2 approved] |
| title_sort | prevalence study of intermittent hormonal therapy of prostate cancer patients in spain version 2 peer review 2 approved |
| topic | intermittent androgen deprivation therapy (IAD) LHRH analogues prostate cancer appropriateness eng |
| url | https://f1000research.com/articles/10-1069/v2 |
| work_keys_str_mv | AT iratxeurreta prevalencestudyofintermittenthormonaltherapyofprostatecancerpatientsinspainversion2peerreview2approved AT joseignaciopijoan prevalencestudyofintermittenthormonaltherapyofprostatecancerpatientsinspainversion2peerreview2approved AT joseantoniocordero prevalencestudyofintermittenthormonaltherapyofprostatecancerpatientsinspainversion2peerreview2approved AT ariadnaauladellrispau prevalencestudyofintermittenthormonaltherapyofprostatecancerpatientsinspainversion2peerreview2approved AT ignasigich prevalencestudyofintermittenthormonaltherapyofprostatecancerpatientsinspainversion2peerreview2approved AT javierzamora prevalencestudyofintermittenthormonaltherapyofprostatecancerpatientsinspainversion2peerreview2approved AT luiscarlossaiz prevalencestudyofintermittenthormonaltherapyofprostatecancerpatientsinspainversion2peerreview2approved AT xavierbonfillcosp prevalencestudyofintermittenthormonaltherapyofprostatecancerpatientsinspainversion2peerreview2approved |